Patients with acute myeloid leukemia (AML) who relapse after first-line treatment face a substantial health care resource utilization (HCRU) and cost burden, according to a poster presented at Virtual ISPOR 2021.
The majority of patients with acute myeloid leukemia (AML) relapse after first-line treatment, which is associated with substantial health care resource utilization (HCRU) and cost burden. These patients also have a poor prognosis: the median survival after relapse is 4 to 11 months.
A retrospective analysis presented at the Virtual ISPOR 2021 meeting highlighted the substantial HCRU burden and costs in the United States and found that 82% of the costs in the first 12 months after relapse comprise inpatient resource utilization.
“Characterizing hospitalization patterns and associated costs of relapsed AML is important for understanding the burden of relapsed AML and the potential clinical and economic benefits of therapies for AML,” the authors wrote.
The researchers used data from the Premier Healthcare Database to examine annual HCRU and associated costs for patients with diagnosed relapsed AML. The database is a large, geographically diverse, hospital-based, all-payer database containing the administrative, health care utilization, and cost data from more than 1 billion patient encounters from more than 1041 hospitals.
The study included 2290 patients with relapsed AML. To be included, patients needed to be ≥ 18 years; have a relapsed AML diagnosis between January 1, 2016, and March 31, 2019; have a prior visit to the same hospital within 2 years; have no relapsed AML diagnosis in the 2 years before the index period (the relapse date); have no stem cell transplantation in the 2 years before the index period; and have no missing billing records.
The mean (SD) age of the patients included was 61.2 (15.7) years, and approximately half (50.2%) were ≥ 65 years. The majority were male (53.1%), White (77.8%), and on Medicare (51.2%). The mean Charlson Comorbidity Index score was 4.02 (2.66) and the most common condition was diabetes (31.0%), followed by congestive heart failure (19.5%) and chronic obstructive pulmonary disease (19.0%).
In the first 12 months after relapse, patients incurred 1798 inpatient hospitalizations:
The mean (SD) cost per visit was $34,209 ($33,838) for inpatient admissions, $19,050 ($19,019) for ICU admissions, and $1793 ($1964) for outpatient visits. In addition, the total cost for patients with AML relapse was $169,643,544.
Slightly less than half (48.4%) had an elective admission, which meant their “condition permitted adequate time to schedule the availability of a suitable accommodation,” while 29.9% were considered emergency, 17.6% urgent, and 4.1% other.
Most (69.4%) patients were discharged home after the visit; however, 6.4% died in the hospital. In addition, 6.4% were discharged to hospice care and 6.3% were transferred to another facility. For 11.2% of the patients, the discharge was other or unknown. The mean length of follow-up was 187 days for patients.
“This study demonstrates significant disease burden, which suggests the need for therapies that would delay relapse and improve survival in patients with AML,” the researchers concluded.
Reference
Huggar D, Knoth R, Cao Z, Lipkin C, Copher R, LeBlanc TW. Annual healthcare resource utilization and costs in US patients diagnosed with relapsed acute myeloid leukemia. Presented at: Virtual ISPOR 2021; May 17-20. Poster PCN51.
Health Equity Adjustments in Medicare HVBP Program Will Benefit Safety Net Hospitals, Study Says
March 29th 2024Medicare’s upcoming health equity adjustment in the Hospital Value-Based Purchasing (HVBP) program will reduce disproportionate penalization among safety net hospitals and those serving high proportions of Black patients, according to a recent study.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
Health Equity and Access Weekly Roundup: March 23, 2024
March 23rd 2024The Center on Health Equity and Access covered disparities in hypertension, diabetic eye health, and hidradenitis suppurativa, along with the proposed legislation banning diversity, equity, and inclusion efforts in Alabama schools and the consequences in sickle cell care from the CDC guideline for opioid prescriptions.
Read More
Mirvetuximab Soravtansine-gynx Granted Full FDA Approval for FRα+ Platinum-Resistant Ovarian Cancer
March 22nd 2024Mirvetuximab soravtansine-gynx (Elahere) received full FDA approval for the treatment of folate receptor alpha–positive (FRα+), platinum-resistant ovarian cancer (PROC) based on findings from the confirmatory phase 3 MIRASOL trial.
Read More